

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



## **Suzhou Basecare Medical Corporation Limited**

**蘇州貝康醫療股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock Code: 2170)**

### **VOLUNTARY ANNOUNCEMENT NMPA APPROVAL OF CLASS III MEDICAL DEVICE REGISTRATION CERTIFICATE FOR GEMS CLEAVAGE EMBRYO CULTURE MEDIUM**

This announcement is made by Suzhou Basecare Medical Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that the Company recently successfully obtained the national Class III medical device registration certificate for its independently developed Gems cleavage embryo culture medium (registration certificate No.: Guo Xie Zhu Jin 20263180177). Prior to such approval, the Gems cleavage embryo culture medium had already obtained the European conformity (conformité européenne) (“**CE**”), the US Food and Drug Administration (“**FDA**”) certification and the Therapeutic Goods Administration of Australia (“**TGA**”) certification.

The Gems cleavage embryo culture medium, built upon 30 years of technological expertise from the Sydney IVF Center and refined through 13 years of overseas clinical validation, has been iteratively upgraded based on patient clinical characteristics and actual diagnostic and treatment needs. With the addition of multiple antioxidant components and precisely optimized nutrient ratios, it retains the high stability advantages of the original formulation while further enhancing early embryo stress resistance and developmental support, making it better suited to the clinical needs of assisted reproduction in China.

Such approval marks the full certification of all four core primary culture products of the Gems series, completing the complete series of sequential culture media, establishing a complete compliant layout for the core categories of embryo culture and building a key closed loop in the full-cycle culture system to provide clinicians with a highly flexible range of choices.

**Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Suzhou Basecare Medical Corporation Limited**  
**Dr. Liang Bo**  
*Chairman and General Manager*

Suzhou, PRC, May 13, 2026

*As at the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Ms. JIANG Junchao as executive Directors; Mr. ZHAO Ye and Mr. WANG Weipeng as non-executive Directors; and Dr. KANG Xixiong, Mr. LAM Siu Wing and Dr. YEUNG Shu Biu William as independent non-executive Directors.*